Nearly three weeks ago, Dr. Erica Schwartz sat before the Senate Committee on Health, Education, Labor and Pensions facing pointed questions about vaccines, autism, and whether she could remain independent while serving under Health and Human Services Secretary Robert F. Kennedy Jr. This week, those questions took on new significance.
On Wednesday, the U.S. Senate voted 51-44 to confirm Schwartz as director of the Centers for Disease Control and Prevention (CDC), ending nearly a year of uncertainty at the nation’s leading public health agency. The confirmation installs the first permanent CDC director in months after a period marked by leadership turnover, thousands of staff departures, and growing questions about the agency’s future.
For many autism families, however, the confirmation is less of an ending than the beginning of a new chapter.
From Confirmation Hearing to Corner Office
During her confirmation hearing, Schwartz sought to reassure lawmakers that scientific evidence, not politics, would guide her leadership.
Pressed repeatedly about vaccines and autism, she acknowledged that the current body of scientific evidence does not support a causal relationship between routine childhood vaccinations and autism. She also pledged that she would “never betray the science” and promised what she described as “radical transparency” to help rebuild public confidence in the CDC.
Those comments stood out because they came at a time when many public health experts have expressed concern about the direction of federal vaccine policy under Kennedy.
Now, as director, Schwartz will have the opportunity (and the challenge) of turning those assurances into policy.
Understanding Who Actually Runs What
One of the biggest misconceptions about the CDC director’s role is that the position operates independently.
It does not.
The CDC is one of several agencies housed within the U.S. Department of Health and Human Services (HHS), alongside the National Institutes of Health (NIH), the Food and Drug Administration (FDA), the Centers for Medicare & Medicaid Services (CMS), and several other federal health agencies.
While the CDC director oversees the agency’s day-to-day operations—including disease surveillance, outbreak response, public health recommendations, and many research programs—the position ultimately reports to the Secretary of Health and Human Services.
That means Kennedy has broad authority over departmental priorities, budgets, appointments, and major policy initiatives. Although CDC scientists develop recommendations and guidance, the secretary exercises significant influence over the department’s direction.
For Schwartz, that reporting relationship will likely define much of her tenure.
A Potential Collision Over Vaccines
The issue drawing the most attention is vaccines.
During her confirmation process, Schwartz emphasized evidence-based medicine and publicly declined to endorse claims that vaccines cause autism. Those statements aligned with decades of research conducted by scientists around the world.
Kennedy, by contrast, has spent years questioning vaccine safety and has continued to reshape federal vaccine policy since becoming HHS secretary. During his tenure, vaccine advisory structures have changed, recommendations have been revisited, and several public health decisions have generated significant debate among physicians and researchers.
That does not necessarily mean the two officials will clash publicly. But it does create an unusual dynamic.
The CDC director is expected to lead the nation’s premier public health agency using scientific evidence, while serving within a department led by a secretary whose views on vaccines have often differed from the scientific consensus.
Whether Schwartz can maintain scientific independence while advancing the administration’s priorities may become one of the defining questions of her leadership.
Why Autism Families Are Watching Closely
For families affected by autism, the stakes extend well beyond vaccine debates.
The CDC plays a central role in autism surveillance through the Autism and Developmental Disabilities Monitoring (ADDM) Network, which tracks autism prevalence across selected communities in the United States. Those reports influence research priorities, educational planning, healthcare systems, and policy discussions nationwide.
The agency also funds autism-related research, supports early identification efforts, publishes developmental resources for families and clinicians, and helps state and local health departments monitor developmental disabilities.
As a result, autism advocates will likely be watching several issues closely over the coming months:
Whether CDC autism resources remain consistent and evidence-based.
Whether autism surveillance and prevalence reporting continue without interruption.
How future research priorities are balanced among genetics, environmental factors, early identification, services, and other areas of investigation.
Whether public messaging about vaccines continues to reflect the current scientific evidence.
These questions are particularly important because autism policy intersects with multiple HHS agencies—not just the CDC. The NIH funds biomedical research, the Administration for Children and Families oversees early childhood programs, CMS influences Medicaid-funded services, and the CDC provides surveillance and public health guidance. Decisions made by HHS leadership can therefore affect autism policy across several federal agencies simultaneously.
Rebuilding an Agency
Beyond policy, Schwartz inherits an agency facing significant internal challenges.
The CDC has experienced substantial workforce losses, leadership instability, and declining morale over the past year. Rebuilding confidence among employees, state health departments, physicians, researchers, and the public may prove just as important as responding to the next public health emergency.
Trust, once lost, is difficult to restore.
That will require not only clear communication, but also consistency between scientific recommendations and departmental actions.
What Comes Next
Schwartz’s confirmation ends months of uncertainty over who would permanently lead the CDC. It does not end the broader debate over the agency’s future.
Families should expect the first signs of her leadership to emerge through CDC guidance, public communications, advisory committee activity, research priorities, and future budget proposals. Congressional oversight hearings may also provide insight into how the agency navigates areas where scientific recommendations and political priorities intersect.
During her confirmation hearing, Schwartz assured senators that she would follow the science and protect the integrity of the CDC. Those commitments helped earn Senate approval.
Now comes the more difficult task.
Leading the CDC has always required balancing science, public communication, and federal policy. Under an HHS secretary whose views on vaccines have frequently drawn national attention, that balancing act may become more visible, and more consequential, than at any point in recent history.